Aktienanalyse zu INmune Bio Inc (INMB)INMBINmune Bio Inc

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

INmune Bio Inc is a good buy right now due to its recent submission of an Orphan Drug Application for Ebstrocel, which could grant 10 years of market exclusivity, and a significant 95% reduction in Q2 net loss to $1.27 million. The current price of $2.33 is well below the analyst target of $9, suggesting substantial upside. However, the main risk is the company's ongoing net losses, with a net income of -$1.27 million in Q2 2026.